Revised ICER evidence report confirms judgment on aducanumab for Alzheimer's

30 June 2021
icer_big

US health technology assessor the Institute for Clinical and Economic Review (ICER) today released its revised Evidence Report assessing the comparative clinical effectiveness and value of Biogen’s (Nasdaq: BIIB) aducanumab – now trade-named Aduhelm - for the treatment of Alzheimer’s disease.

“Individuals and families dread Alzheimer’s disease, and the first therapy that effectively halts or reverses dementia will warrant a very high price in the US health system,” said Dr David Rind, the ICER’s chief medical officer. “However, the clinical trial history and evidence regarding aducanumab are complex, and we agree with  many independent experts that the current evidence is insufficient to know whether or not aducanumab slows the loss of cognition. Many other drugs have been shown to remove amyloid from the brain yet failed to improve the lives of those with Alzheimer’s disease; none of these other treatments received FDA approval” he added.

Key clinical findings

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology